-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with Alzheimer's disease (AD) urgently need effective new therapies, but the effects of many drugs under investigation in clinical trials are not ideal.
In this research, scientists used machine learning technology to build an artificial intelligence system called Drug Repurposing In Alzheimer's Disease (DRAID).
The DRIAD system works by measuring the changes in human brain nerve cells after drug treatment.
After screening 80 FDA-approved drugs, the researchers listed the top 15 potential drug candidates.
Among them, anti-inflammatory drugs belong to JAK kinase inhibitors.
"Using FDA-approved drugs for the treatment of Alzheimer's disease is an attractive idea that can accelerate the development of innovative therapies.